NASDAQ: RAPTRapt Therapeutics Inc Stock
$34.04+0.86 (+2.59%)
Updated Dec 18, 2025
RAPT Price
$34.04
Fair Value Price
$32.43
Market Cap
$943.28M
52 Week Low
$5.67
52 Week High
$42.39
P/E
-2.92x
P/B
6.21x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$105.64M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.09
Operating Cash Flow
-$87M
Beta
1.78
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RAPT Overview
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RAPT's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RAPT
Ranked#139 of 488
Ranked#139 of 488
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $396.04 | A | |
| $20.07 | A | |
| $307.02 | A |
Be the first to know about important RAPT news, forecast changes, insider trades & much more!
RAPT News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RAPT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RAPT ($34.04) is overvalued by 4.96% relative to our estimate of its Fair Value price of $32.43 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RAPT ($34.04) is not significantly undervalued (4.96%) relative to our estimate of its Fair Value price of $32.43 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RAPT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RAPT due diligence checks available for Premium users.
Valuation
RAPT fair value
Fair Value of RAPT stock based on Discounted Cash Flow (DCF)
Price
$34.04
Fair Value
$32.43
Overvalued by
4.96%
RAPT ($34.04) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RAPT ($34.04) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RAPT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RAPT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.92x
Industry
153.71x
Market
44.14x
RAPT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.21x
Industry
5.15x
RAPT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RAPT's financial health
Profit margin
Revenue
$0.0
Net Income
-$17.6M
Profit Margin
0%
RAPT's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$165.7M
Liabilities
$13.8M
Debt to equity
0.09
RAPT's short-term assets ($161.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RAPT's short-term assets ($161.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RAPT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
RAPT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.5M
Investing
$8.5M
Financing
$36.0k
RAPT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RAPT vs Biotech Stocks
Rapt Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.